Respiratory Syncytial Virus Antivirals: Problems and Progress

J Infect Dis. 2020 Oct 1;222(9):1417-1421. doi: 10.1093/infdis/jiaa029.

Authors

Frederick G Hayden¹, Richard J Whitley²

Affiliations

¹ Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
² Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

PMID: 31974551
DOI: 10.1093/infdis/jiaa029

No abstract available

Keywords: antivirals; respiratory syncytial virus; therapeutics.

Publication types

Editorial
Comment

MeSH terms

Anti-Retroviral Agents / therapeutic use
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use
Drug Resistance / drug effects
Humans
Respiratory Syncytial Virus Infections* / drug therapy
Respiratory Syncytial Virus Infections* / epidemiology
Respiratory Syncytial Virus, Human* / drug effects

Substances

Anti-Retroviral Agents
Antiviral Agents